Alcon LenSx and Johnson & Johnson Catalys financing for cataract groups, from 5.49% APR, with seasonal payments an option.
No cost, no obligation, no credit impact.
Bank-level encryption. Your info is confidential.
Trusted by 1,000+ businesses nationwide
"I've worked with Brobas for a long time. They provided financing with a minimal down payment, which was crucial for me. Since then, I've grown with them and plan to open a fourth location."
Nikola T.
Fleet Owner
"The first day after submitting documents, they gave me a full breakdown of my situation and explained the strategy. I got a great offer, and now the truck works for me, not the other way around."
Oleh O.
Owner-Operator
"Brobas has great relationships with banks. The monthly payment they offered was comparable, if not lower, than equipment financing. You won't get the same terms walking into a street bank."
Natalya P.
Business Owner
Femtosecond laser assisted cataract surgery is the premium tier of the cataract practice. The laser performs the capsulotomy, fragments the lens, and creates the corneal and arcuate incisions with a precision that supports toric and presbyopia-correcting lenses, and the refractive portion is patient pay, typically $1,500 to $3,500 per eye out of pocket. The catch is the box. An Alcon LenSx or a Johnson & Johnson Catalys with the LIQUID OPTICS interface is a $400,000 to $550,000 capital decision, before the per-procedure patient interface disposables and the service contract. Brobas Capital Partners is a US equipment finance broker with more than 500 lenders, and we structure FLACS financing for cataract groups and ambulatory surgery centers. We know these platforms carry seasonal surgical volume, so we can build seasonal or step payments that flex with your case load, and we finance the disposables and service into the deal. Approvals start from 5.49% APR for qualified groups, and you keep your operating capital and bank lines intact.
Cataract volume swings by season. We can build step or seasonal payment structures so the laser payment tracks your case load.
Patient interface packs and the annual service contract folded into the deal, not a separate cash drain every quarter.
A half-million-dollar box off your bank line keeps your capital free for staff, real estate, and additional ORs. From 5.49% APR.
Deduct the full price the year it is placed in service, with 100% bonus depreciation available on top. Confirm with your CPA.
Fill out a quick 5-minute application. No impact on your credit score.
Our AI engine matches you with the best lenders from our 500+ network.
Review competitive offers with transparent rates and terms.
Choose your best option and receive funding, often within days.
Standard cataract surgery is a covered procedure with a fixed facility and professional reimbursement. The femtosecond laser does not change that baseline. What it opens is the refractive upgrade, and that is where the economics live. When a patient elects a toric or presbyopia-correcting lens (an Alcon PanOptix, a Vivity, or a Johnson & Johnson Symfony) and the laser-assisted astigmatic correction that goes with it, the refractive portion is not billed to Medicare. It is patient pay, commonly $1,500 to $3,500 per eye, collected up front.
The Alcon LenSx is the most widely placed platform, integrated tightly with Alcon's IOL and diagnostic ecosystem. The Johnson & Johnson Catalys with its LIQUID OPTICS liquid immersion interface is prized for a gentle docking and a clear imaging field. Both run $400,000 to $550,000 depending on configuration, and both carry a per-case patient interface disposable (often in the $300 to $500 range) plus an annual service contract.
A cataract surgeon reads that and immediately does the conversion math: what share of patients elect the premium channel, at what per-eye fee, across how many cases. The laser is justified by the refractive conversion, not the covered procedure, which is exactly why the payment should be structured around surgical volume rather than a flat bank note.
Recent Brobas femtosecond laser approvals, rounded to protect the practices:
- Miami cataract group, Alcon LenSx. $525,000 financed. An established multi-surgeon group, 770 credit. Approved at 5.49% APR over 72 months, $0 down, with seasonal step payments tied to surgical volume so the lighter summer months carry a lower payment. This is the structure behind our headline.
- Orlando ophthalmology practice, Johnson & Johnson Catalys. $465,000 financed. Twelve years in practice, 758 credit. Approved at 5.74% APR over 84 months with 10% down.
- Dallas refractive surgeon, LenSx with the service contract bundled. $498,000 financed. Fifteen years in practice, 765 credit. Approved at 5.64% APR over 66 months with the first payment deferred 90 days.
- Phoenix ASC adding FLACS, Catalys. $442,000 financed. An eight-year surgery center, 744 credit. Approved at 6.19% APR over 72 months with 15% down.
Rates ran from 5.49% to 6.19% based on time in practice, credit strength, and structure. These were earned terms, not advertised rates, and none were guaranteed. Six-figure and larger tickets like these usually involve basic financials, and we place them across more than 500 lenders to find the group that prices your file best.
The question that decides a FLACS purchase is refractive conversion. Take a surgeon doing 60 cataract cases a month. If 25% elect the premium refractive channel at an average of $2,500 per eye of patient-pay revenue, that is 15 eyes at $2,500, or roughly $37,500 a month of non-covered production the laser enables. Against a LenSx payment near $7,500 to $8,500 a month, the platform clears its own cost with meaningful room, and higher conversion or a second surgeon on the box widens the margin fast. Subtract the per-case disposable and service, model your own conversion honestly, and the picture is usually clear.
Section 179 applies even at this scale. The annual deduction cap runs into the millions, above the cost of a single laser, so a qualifying practice can deduct the full purchase price in the year the equipment is placed in service, with 100% bonus depreciation available on top under current law. A half-million-dollar asset placed in service before year end can generate a very large same-year deduction while your cash outlay is only a few months of payments. For a high-earning surgical group, that timing is a genuine tax lever, not a footnote. Run it with your CPA against your entity structure and the year you place the laser in service.
A half-million-dollar surgical laser should not go on your bank line. Tying up that much borrowing capacity starves the rest of the practice: staffing, real estate, a second OR, or the phaco system next to the femto. As a broker with more than 500 lenders, we structure FLACS deals to protect your capital:
- Terms from 60 to 84 months, matching the payment to the laser's long service life and keeping the monthly manageable.
- Seasonal and step payments. Cataract volume is seasonal in many markets, so we can build lower payments into the slow months and higher ones into the busy quarters.
- Disposables and service financed in. The patient interface packs and the annual service contract can be folded into the transaction instead of hitting cash flow separately.
- Deferred first payments of 30 to 90 days for a new ASC room or a new platform, so the laser is generating refractive revenue before the payment starts.
Tickets this size typically involve financials and, for newer or challenged-credit groups, a down payment of 10% to 15%. Established groups often qualify at $0 down. Send us the Alcon or Johnson & Johnson quote, tell us your surgical volume, and we will build a structure that flexes with it, from 5.49% APR for qualified groups.
An Alcon LenSx or Johnson & Johnson Catalys runs $400,000 to $550,000 depending on configuration, before per-case disposables and the service contract. Financed over 60 to 84 months, most groups see a payment roughly in the $6,000 to $9,000 range, from 5.49% APR for qualified groups.
Yes, and it is one of the main reasons cataract groups use us. Because we place across more than 500 lenders, we can structure step or seasonal payments that run lower in slow months and higher in busy quarters, so the laser payment tracks your case load rather than fighting it.
Often, yes. The per-case patient interface packs and the annual service contract can be folded into the financing so they do not hit cash flow as separate quarterly expenses. We build the full cost of ownership into one structure.
It is justified by refractive conversion, not the covered procedure. The premium channel (toric and presbyopia-correcting lenses with laser astigmatic correction) is patient pay at commonly $1,500 to $3,500 per eye. At typical conversion rates and volumes, the non-covered revenue usually clears the payment with room. Model your own conversion with your CPA.
Generally yes. The Section 179 cap runs into the millions, above a single laser's cost, so a qualifying practice can deduct the full price the year it is placed in service, with 100% bonus depreciation available on top under current law. Confirm with your CPA.
Tickets in the hundreds of thousands typically involve basic financial statements. Established groups often qualify at $0 down, while newer or challenged-credit practices may put 10% to 15% down. Decisions usually come back within a few business days.
No cost, no obligation, no credit impact.
Bank-level encryption. Your info is confidential.